Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

426
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
426
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

490
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
490
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

253
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
253
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

996
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
996
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.6K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.6K
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-scale data improves performance of machine learning model for long COVID identification.

Communications medicine·2026
Same author

Governing real-world health data as a public utility.

Science (New York, N.Y.)·2026
Same author

LinkML: an open data modeling framework.

GigaScience·2025
Same author

Development of a robust corpus for automated evaluation of online health information in Chinese using the DISCERN scale.

Journal of the American Medical Informatics Association : JAMIA·2025
Same author

Advancing the science of genomic learning healthcare systems.

Learning health systems·2025
Same author

Mondo: integrating disease terminology across communities.

Genetics·2025
Same journal

LabSage: Structural-Semantic Decoupling for Enhanced Retrieval-Augmented Generation in Clinical Laboratories.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

Evaluating Representation Embeddings from LLMs and Time-Series Foundation Models for Wearable Accelerometer-Based Health Prediction.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

ClinNoteAgents: An LLM Multi-Agent System for Predicting and Interpreting Heart Failure 30-Day Readmission from Clinical Notes.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

Mapping the Storm: Linking Tornado Paths to Emergency Room Surges Through Geocoded Patient Data.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

Multi-Modal Deep Learning-Based Model to Predict Burkitt Lymphoma Recurrence.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

A Multi-Model LLM Consensus Framework to Identify EHR-Predictable Eligibility Criteria in NSCLC Immunotherapy Trials.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization
08:27

Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization

Published on: July 27, 2021

4.6K

Using clinical element models for pharmacogenomic study data standardization.

Qian Zhu1, Robert R Freimuth, Jyotishman Pathak

  • 1Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science
|December 5, 2013
PubMed
Summary
This summary is machine-generated.

Standardizing pharmacogenomics data with Clinical Element Models (CEMs) improves data integration. This study successfully applied SHARPn CEMs to pharmacogenomics data, identifying areas for future development.

More Related Videos

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

16.6K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

9.2K

Related Experiment Videos

Last Updated: May 5, 2026

Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization
08:27

Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization

Published on: July 27, 2021

4.6K
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

16.6K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

9.2K

Area of Science:

  • Bioinformatics
  • Pharmacogenomics
  • Health Informatics

Background:

  • Pharmacogenomics data often lacks standardized representations, leading to heterogeneity and hindering reuse.
  • Data integration challenges impede comprehensive analysis in pharmacogenomics research.

Purpose of the Study:

  • To represent pharmacogenomics data elements using Clinical Element Models (CEMs).
  • To assess the applicability of SHARPn CEMs to the pharmacogenomic domain.
  • To identify gaps in current CEMs for pharmacogenomics data.

Main Methods:

  • Grouped Pharmacogenomics Research Network (PGRN) data elements by UMLS semantic type.
  • Mapped PGRN data elements to Clinical Element Model (CEM) attributes.
  • Utilized a web-based tool for data curation and mapping.

Main Results:

  • Demonstrated successful application of SHARPn CEMs to pharmacogenomics data.
  • Identified specific data element categories not yet supported by SHARPn CEMs.
  • Highlighted opportunities for CEM development in pharmacogenomics.

Conclusions:

  • Clinical Element Models (CEMs) offer a viable approach for standardizing pharmacogenomics data.
  • Further development of CEMs is needed to encompass all pharmacogenomics data types.
  • Standardization efforts facilitate data exchange and integration in pharmacogenomics.